Notch Therapeutics announced that it will shut down its lab in Vancouver, B.C., and lay off about 25 employees, with some offered relocation options.
- “Our goal is to build on core capabilities in Toronto and Seattle as we continue to develop our cell therapy pipeline. Notch has been making steady progress towards developing best-in-class iPSC-derived T cells, but we are making changes to sharpen our focus and ensure we remain operationally efficient during these externally challenging and turbulent times,” the company said in a statement.
- The company launched in 2018 and is developing stem cell-derived immunotherapies for cancer. It has about 20 employees in Seattle and expects to grow headcount.
- Notch raised a $85 million Series A round in 2021.
Editor’s note: Story updated with more details on number of employees affected and Seattle headcount.
